Why Alpha Particles Are Challenging Beta-Emitter Dominance in PSMA Therapy
Actinium-225 targeted alpha therapy works by delivering high linear energy transfer (LET) radiation directly to tumor cells, causing irreparable DNA double-strand breaks within a tissue path length of approximately 80 µm — a physical precision that beta-emitting isotopes such as lutetium-177 (¹⁷⁷Lu) cannot match. This short path length is not merely a technical detail; it is the central argument for why ²²⁵Ac-based radioligand therapy (RLT) is attracting serious patent and clinical investment as a successor to the established ¹⁷⁷Lu-PSMA-617 platform.
The scientific rationale for ²²⁵Ac over ¹⁷⁷Lu rests on three converging arguments articulated across the patent record. First, alpha particles are proposed to overcome resistance mechanisms that emerge with beta-particle radiation — a clinically relevant concern given that mCRPC patients progressing on ¹⁷⁷Lu-PSMA-617 represent a growing and underserved population. Second, the short path length may reduce hematological toxicity in patients with diffuse bone metastases, where ¹⁷⁷Lu’s longer-range beta emissions can reach bone marrow. Third, early clinical observations cited by Cornell University researchers describe preliminary treatment of human patients with ²²⁵Ac-PSMA-617 or ²¹³Bi-PSMA-617 in refractory cancer as producing substantial responses, providing a proof-of-concept that motivates the current wave of IP filings.
PSMA (prostate-specific membrane antigen, encoded by the FOLH1 gene) remains the pre-eminent molecular target across all retrieved RLT-relevant records. Patent filings emphasise that PSMA expression increases with tumor aggressiveness — it is highest in metastatic, castration-resistant, and androgen-independent disease — and is expressed on the tumor neovasculature of most solid tumors including lung, colon, pancreatic, renal, and melanoma, but not on normal vasculature. This broad expression profile, combined with established imaging infrastructure via PSMA-PET, makes it the natural anchor target for ²²⁵Ac conjugate development, as documented by bodies including WIPO in its annual technology trend reports on radiopharmaceuticals.
Targeted alpha therapy (TAT) uses alpha-particle-emitting radioisotopes conjugated to tumor-targeting vectors (small molecules, peptides, or antibodies) to deliver high LET radiation selectively to cancer cells. ²²⁵Ac and its decay daughters emit multiple alpha particles per decay chain, amplifying cytotoxic effect at the tumor site while the short path length (~80 µm) theoretically limits damage to surrounding healthy tissue.
Actinium-225 (²²⁵Ac) targeted alpha therapy generates high linear energy transfer radiation that causes irreparable DNA double-strand breaks within a tissue path length of approximately 80 µm, enabling targeted tumor kill while theoretically limiting bystander toxicity in surrounding healthy tissue.
Clinical Translation: What the Patent Record Reveals About ²²⁵Ac-PSMA-617 Trials
The most advanced clinical signals for ²²⁵Ac targeted alpha therapy in this dataset are embedded in Novartis patent filings, which disclose completed Phase 1 dose-escalation data and an ongoing randomized Phase 2 study — a level of clinical granularity unusual in patent documents and indicative of active trial execution. The recommended Phase 2 dose (RP2D) for ²²⁵Ac-radiolabeled PSMA-617 has been established at 6 MBq or 8 MBq, derived from a prior dose-escalation study, according to a Novartis CN filing.
“Preliminary treatment of human patients with ²²⁵Ac-PSMA-617 or ²¹³Bi-PSMA-617 has produced enormous responses in refractory cancer.” — Cornell University patent filing, 2024
The Novartis Phase 2 study design disclosed in patent filings compares ²²⁵Ac-PSMA-617 against best standard of care (BSoC) in men with mCRPC who have received prior taxane chemotherapy. Patient eligibility criteria disclosed in the patent — including prior taxane therapy, absence of spinal cord compression, and specific co-morbidity exclusions — are consistent with an ongoing interventional clinical study. This level of operational detail in a patent filing is a strong signal that the program is actively enrolling or has recently completed enrollment.
Novartis AG has established a recommended Phase 2 dose (RP2D) of 6 MBq or 8 MBq for ²²⁵Ac-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC), based on a completed dose-escalation study cited in patent filings, with a randomized Phase 2 study versus best standard of care described in a Chinese jurisdiction filing.
For ¹⁷⁷Lu-PSMA, the clinical evidence base is further advanced: Novartis TW and BR filings disclose ¹⁷⁷Lu-PSMA-617 (lutetium vipivotide tetraxetan) for taxane-naïve mCRPC patients who have progressed after second-generation androgen receptor pathway inhibitor (ARPI) therapy, with patient selection based on PSMA-positive imaging. This established clinical framework — including PSMA-PET patient selection, dose-response infrastructure, and ARPI pre-treatment requirements — is directly applicable to ²²⁵Ac program design and is expected to accelerate IND-enabling and Phase 2 regulatory pathways for alpha-emitter successors, as frameworks published by the European Medicines Agency on radiopharmaceutical development have increasingly acknowledged.
Track ²²⁵Ac-PSMA-617 patent filings and clinical signals across all jurisdictions in real time.
Explore full patent data in PatSnap Eureka →The Cornell University filing adds a translational dimension: it explicitly references the early clinical use of ²²⁵Ac-PSMA-617 and ²¹³Bi-PSMA-617 in heavily pretreated patients as the proof-of-concept motivating development of albumin-binding, pharmacokinetically optimised trifunctional constructs. Preclinical work with ²¹³Bi-PSMA I&T confirmed in vivo DNA double-strand break formation, providing mechanistic validation for the clinical observations. For context on the broader radiopharmaceutical regulatory environment, the FDA‘s guidance on targeted radiotherapy has been instrumental in shaping trial design requirements for alpha-emitting agents.
Who Holds the IP: Assignee Landscape and Strategic Positioning
Innovation in ²²⁵Ac targeted alpha therapy for prostate and neuroendocrine tumors is concentrated among a small set of commercial and academic entities, with activity predominantly patent-driven and spanning multiple jurisdictions. Novartis AG holds the most advanced commercial position, with filings across CN, TW, and BR jurisdictions covering both ²²⁵Ac-PSMA-617 clinical regimens and the established ¹⁷⁷Lu-PSMA-617 (lutetium vipivotide tetraxetan) platform.
Fusion Pharmaceuticals holds a specific IP position in ²²⁵Ac small-molecule PSMA conjugates (Formula I) and their combination with DNA damage response inhibitors, representing a targeted niche strategy distinct from Novartis’s broader clinical program. The Fusion filing explicitly discloses that ²²⁵Ac can be quantitatively chelated at room temperature within one hour — a practical manufacturing advantage with IP implications.
Bayer AG is active in PSMA-targeted antibody-based radioligand conjugates with ²²⁵Ac chelation chemistry. Its filing notes that Ac-225 chelation is quantitatively achievable at room temperature within one hour, forming complexes with a clearly lower collateral activity ratio (CAR) compared to alternative chelation methods — a differentiation claim with both technical and IP significance. The Johns Hopkins University is the leading academic assignee, contributing PSMA endoradiotherapy chemistry (filed in ES jurisdiction) and the dual FAP-α/PSMA heterobivalent ligand platform. Cornell University contributes a trifunctional construct with albumin-binding pharmacokinetic modulation, explicitly referenced as adaptable to ²²⁵Ac labeling.
Fusion Pharmaceuticals Inc. holds patent IP disclosing that Actinium-225 (²²⁵Ac) can be quantitatively chelated at room temperature within one hour for use in PSMA-targeted small-molecule radiopharmaceuticals, with combination use alongside DNA damage response inhibitors (DDRi) described in a 2025 Chinese jurisdiction filing.
Beyond PSMA: Targeting Neuroendocrine Transdifferentiation with NTSR1 and CEACAM5
PSMA expression is not universal in advanced prostate cancer: some late-stage tumors downregulate PSMA following prolonged anti-androgen therapy, undergoing neuroendocrine transdifferentiation that renders them ineligible for PSMA-RLT and, currently, without a validated radioligand therapy alternative. Patent filings from the University of North Carolina at Chapel Hill and Southern Medical University’s Third Affiliated Hospital signal early-stage academic work addressing this unmet need through two distinct molecular targets.
Patent evidence from the University of North Carolina identifies that PSMA is downregulated in some advanced prostate cancers (including androgen-independent PC3 and DU145 cell lines) and that neuroendocrine-like cells become enriched following prolonged anti-androgen therapy. This population is currently outside the PSMA-RLT eligibility window and represents a first-mover IP opportunity for NTSR1- and CEACAM5-targeted alpha therapy constructs.
The University of North Carolina filing discloses NTSR1 (neurotensin receptor 1) ligand SR-CP-05, designed for radiolabeling and NTSR1-positive cancer imaging and therapy. NTSR1 is identified as a radioligand target specifically relevant for PSMA-negative or PSMA-downregulated late-stage prostate tumors that have undergone neuroendocrine transdifferentiation. The chelating moiety in the disclosed compounds accommodates radioisotope binding, potentially including ²²⁵Ac, though no clinical signals are present in the retrieved dataset for this program — it appears to be at the discovery or preclinical stage.
Southern Medical University’s Third Affiliated Hospital (Guangdong Orthopedic Research Institute) discloses nanobody B12 with high affinity for CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5), a surface marker documented as elevated in castration-resistant neuroendocrine prostate cancer (CRPC-NE) and correlated with visceral metastasis. Elevated serum CEA levels are noted as correlating with visceral metastasis in CRPC-NE. The nanobody’s small molecular weight is described as favorable for broad drug development applications, including potential radioligand conjugation. Research published through institutions indexed by NIH/PubMed has increasingly characterised the neuroendocrine prostate cancer phenotype and its distinct surface antigen profile, providing the biological context for these IP filings.
Identify white-space IP opportunities in NTSR1 and CEACAM5 targeted therapy before competitors do.
Analyse Patents with PatSnap Eureka →For neuroendocrine tumors more broadly, retrieved results also highlight SSTR (somatostatin receptor)-related biology as a target relevant to the neuroendocrine phenotype, consistent with the established clinical use of somatostatin analogues in gastroenteropancreatic neuroendocrine tumors. The convergence of NTSR1, CEACAM5, and SSTR-related targets in patent filings signals that the field is actively mapping the molecular landscape of neuroendocrine-transdifferentiated prostate cancer to identify viable radioligand vectors for patients who have exhausted PSMA-directed options.
Combination Strategies: DDRi, Dual Targets, and Pharmacokinetic Engineering
The ²²⁵Ac-PSMA pipeline is not developing in isolation: patent filings reveal at least four structurally distinct combination and engineering strategies that reflect the field’s recognition that monotherapy alpha-particle delivery, while potent, will likely be insufficient for durable responses in heavily pretreated mCRPC. Each strategy addresses a different biological or pharmacological limitation of current RLT platforms.
²²⁵Ac-PSMA + DNA Damage Response Inhibitors
Fusion Pharmaceuticals’ 2025 CN filing is the most specific disclosure of this combination in the retrieved dataset. The mechanistic rationale is that alpha-particle-induced DNA double-strand breaks may be synergistically amplified by concurrent DNA damage response inhibitors (DDRi), improving cancer cell kill without proportionally increasing toxicity in non-PSMA-expressing tissues. This represents an emerging niche with dedicated IP filings and limited incumbency — the Fusion filing is the primary disclosure in this dataset, suggesting early-stage IP positions may still be accessible to competing organisations.
Dual-Target FAP-α/PSMA Heterobivalent Constructs
The Johns Hopkins University platform for simultaneous FAP-α (fibroblast activation protein-α, expressed on tumor stroma) and PSMA (expressed on tumor epithelium and neovasculature) targeting represents a structural innovation designed to address heterogeneous PSMA expression and stroma-rich tumor microenvironments. FAP-α co-targeting provides a complementary strategy: where PSMA expression is heterogeneous or downregulated in some tumor cells, FAP-α expression on the surrounding stroma may maintain radioligand accumulation at the tumor site. The chelation chemistry described in the filing is compatible with radioactive metal complexes, though the filing does not specify which radioisotopes are prioritised.
Albumin-Binding Pharmacokinetic Engineering
The Cornell University trifunctional construct platform incorporates albumin-binding groups to modulate blood clearance rates, enabling higher and more durable tumor accumulation compared to conventional ¹⁷⁷Lu-PSMA-617. The filing explicitly notes this approach as adaptable to ²²⁵Ac labeling and alpha-particle therapy. Pharmacokinetic engineering of this type addresses a known challenge in RLT: the short physical half-life of ²²⁵Ac (approximately 10 days) combined with rapid renal clearance of small-molecule PSMA ligands can limit tumor dose delivery. Albumin-binding modifications extend plasma half-life and increase tumor retention, potentially improving the therapeutic index of ²²⁵Ac conjugates.
The strategic implication of this combinatorial landscape is that the ²²⁵Ac-PSMA-617 monotherapy program (Novartis) is being flanked by differentiated IP strategies addressing its known limitations: PSMA expression heterogeneity (dual-target constructs), suboptimal pharmacokinetics (albumin-binding engineering), resistance mechanisms (DDRi combinations), and PSMA-negative patient populations (NTSR1, CEACAM5). Organisations seeking to enter the ²²⁵Ac TAT space will find the monotherapy PSMA-617 niche increasingly consolidated by Novartis, but the combination and alternative-target spaces remain relatively open — a pattern consistent with how the broader radiopharmaceutical field has evolved, as tracked by PatSnap’s innovation intelligence platform and documented in regulatory science publications from the EMA.
Johns Hopkins University has filed patents disclosing heterobivalent and homodivalent agents targeting both FAP-α (fibroblast activation protein-α, expressed on tumor stroma) and PSMA (prostate-specific membrane antigen, expressed on tumor epithelium and neovasculature) as a dual-target radioligand strategy to address heterogeneous PSMA expression in prostate cancer.